Min‐Hee Ryu
Impact in
- Hepatology top 0.2%
- Hepatocellular Carcinoma Treatment and Prognosis
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Inflammatory Biomarkers in Disease Prognosis
Papers in
-
- Gastric Cancer Management and Outcomes 129
-
- Gastrointestinal Tumor Research and Treatment 55
- Co-authors
- Yoon‐Koo Kang (163 shared papers)Baek‐Yeol Ryoo (82 shared papers)Jae‐Lyun Lee (54 shared papers)Tae Won Kim (43 shared papers)Heung Moon Chang (43 shared papers)Changhoon Yoo (44 shared papers)Hyun Cheol Chung (8 shared papers)Young-Soo Park (46 shared papers)
- Journals
- Gastric Cancer (37 papers)Annals of Oncology (23 papers)Cancer Chemotherapy and Pharmacology (20 papers)Cancer Research and Treatment (17 papers)Investigational New Drugs (12 papers)
- Partner nations
- South KoreaUnited StatesJapan
In The Last Decade
Min‐Hee Ryu
280 papers receiving 15.5k citations
Min‐Hee Ryu's Hit Papers
Peers
Comparison fields: 5 of 116
- Hepatology 2.7k
- Oncology 5k
- Gastroenterology 1.3k
- Pulmonary and Respiratory Medicine 5.5k
- Cancer Research 424
Countries citing papers authored by Min‐Hee Ryu
This map shows the geographic impact of Min‐Hee Ryu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Min‐Hee Ryu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Min‐Hee Ryu more than expected).
Fields of papers citing papers by Min‐Hee Ryu
This network shows the impact of papers produced by Min‐Hee Ryu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Min‐Hee Ryu. The network helps show where Min‐Hee Ryu may publish in the future.
Co-authors
The 25 scholars most cited alongside Min‐Hee Ryu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 293 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma Hit paper breakdown → | 2018 | 1919 |
| 2 | Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2017 | 1869 |
| 3 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1060 |
| 4 | Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer Hit paper breakdown → | 2020 | 1016 |
| 5 | Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 594 |
| 6 | Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study Hit paper breakdown → | 2023 | 528 |
| 7 | Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300 Hit paper breakdown → | 2018 | 414 |
| 8 | PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer Hit paper breakdown → | 2021 | 263 |
| 9 | 2018 | 255 | |
| 10 | 2020 | 184 | |
| 11 | 2019 | 180 | |
| 12 | 2016 | 161 | |
| 13 | 2007 | 160 | |
| 14 | 2013 | 158 | |
| 15 | 2018 | 142 | |
| 16 | 2004 | 135 | |
| 17 | 2013 | 129 | |
| 18 | 2021 | 124 | |
| 19 | 2015 | 108 | |
| 20 | 2013 | 106 |
About Min‐Hee Ryu
Min‐Hee Ryu is a scholar working on Pulmonary and Respiratory Medicine, Gastroenterology, Oncology, Hepatology and Surgery, having authored 293 papers that have together received 15.8k indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (129 papers), Gastrointestinal Tumor Research and Treatment (55 papers), Hepatocellular Carcinoma Treatment and Prognosis (30 papers), Cancer Immunotherapy and Biomarkers (28 papers), HER2/EGFR in Cancer Research (16 papers), Colorectal Cancer Treatments and Studies (9 papers), Lymphoma Diagnosis and Treatment (6 papers) and Inflammatory Biomarkers in Disease Prognosis (5 papers). The work is most often cited by research in Hepatology (2.7k citations), Oncology (5k citations), Gastroenterology (1.3k citations), Pulmonary and Respiratory Medicine (5.5k citations) and Cancer Research (424 citations). Min‐Hee Ryu has collaborated with scholars based in South Korea, United States and Japan. Frequent co-authors include Yoon‐Koo Kang, Baek‐Yeol Ryoo, Jae‐Lyun Lee, Tae Won Kim, Heung Moon Chang, Changhoon Yoo, Hyun Cheol Chung, Young-Soo Park, Jeoung Hwan Yook and Yung‐Jue Bang. Their work appears in journals such as Gastric Cancer, Annals of Oncology, Cancer Chemotherapy and Pharmacology, Cancer Research and Treatment and Investigational New Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.